[go: up one dir, main page]

AU2002346973A1 - Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient - Google Patents

Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient

Info

Publication number
AU2002346973A1
AU2002346973A1 AU2002346973A AU2002346973A AU2002346973A1 AU 2002346973 A1 AU2002346973 A1 AU 2002346973A1 AU 2002346973 A AU2002346973 A AU 2002346973A AU 2002346973 A AU2002346973 A AU 2002346973A AU 2002346973 A1 AU2002346973 A1 AU 2002346973A1
Authority
AU
Australia
Prior art keywords
propiverine
pharmaceutically acceptable
active ingredient
dosage form
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002346973A
Other versions
AU2002346973B2 (en
AU2002346973B8 (en
Inventor
Thomas Gramatte
Peter Gruber
Peter Guldner
Michael Heschel
Dirk Pamperin
Jan Ploen
Steffen Scheithauer
Wolfgang Wehner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogepha Arzneimittel GmbH
Original Assignee
Apogepha Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10149674A external-priority patent/DE10149674A1/en
Application filed by Apogepha Arzneimittel GmbH filed Critical Apogepha Arzneimittel GmbH
Publication of AU2002346973A1 publication Critical patent/AU2002346973A1/en
Publication of AU2002346973B2 publication Critical patent/AU2002346973B2/en
Application granted granted Critical
Publication of AU2002346973B8 publication Critical patent/AU2002346973B8/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

AU2002346973A 2001-10-09 2002-10-08 Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient Expired AU2002346973B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10149674A DE10149674A1 (en) 2001-10-09 2001-10-09 Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
DE10149674.5 2001-10-09
PCT/EP2002/011253 WO2003030869A1 (en) 2001-10-09 2002-10-08 Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient

Publications (3)

Publication Number Publication Date
AU2002346973A1 true AU2002346973A1 (en) 2003-07-03
AU2002346973B2 AU2002346973B2 (en) 2006-10-12
AU2002346973B8 AU2002346973B8 (en) 2006-11-09

Family

ID=7701848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346973A Expired AU2002346973B8 (en) 2001-10-09 2002-10-08 Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient

Country Status (32)

Country Link
US (1) US7943176B2 (en)
EP (1) EP1435915B1 (en)
JP (1) JP4192096B2 (en)
KR (1) KR100723964B1 (en)
CN (1) CN100473382C (en)
AR (1) AR036768A1 (en)
AT (1) ATE401865T1 (en)
AU (1) AU2002346973B8 (en)
CA (1) CA2462482C (en)
CY (1) CY1108426T1 (en)
DE (2) DE10149674A1 (en)
DK (1) DK1435915T3 (en)
EA (1) EA008862B1 (en)
EG (1) EG25542A (en)
ES (2) ES2311068T3 (en)
HR (1) HRP20040323C1 (en)
HU (1) HU227878B1 (en)
IL (2) IL160977A0 (en)
IS (1) IS2571B (en)
JO (1) JO2555B1 (en)
ME (2) MEP44308A (en)
MX (1) MXPA04003132A (en)
MY (1) MY142403A (en)
PE (1) PE20030399A1 (en)
PL (1) PL208229B1 (en)
PT (1) PT1435915E (en)
RS (1) RS50924B (en)
SI (1) SI1435915T1 (en)
TW (1) TWI315204B (en)
UA (1) UA75727C2 (en)
WO (1) WO2003030869A1 (en)
ZA (1) ZA200402437B (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10149674A1 (en) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Dosage form to be administered orally for poorly soluble basic active ingredients
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
AU2004285284B2 (en) * 2003-10-31 2010-03-25 Hexal Ag A process for the preparation of an active-ingredient-containing formulation with a coating
DE10353186A1 (en) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form containing a modulatory substance in relation to the release of active ingredient
DE10353196A1 (en) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form with a matrix influencing the delivery of a modulatory substance
EP1683525B1 (en) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006046560A1 (en) * 2004-10-29 2006-05-04 Taiho Pharmaceutical Co., Ltd. Propiverine-containing oral particulate preparation and process for producing the same
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
RU2403033C2 (en) 2005-03-22 2010-11-10 Лозан Фарма Гмбх Solubilised ibuprofen
JP2008534530A (en) * 2005-03-29 2008-08-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング Multiparticulate drug form containing pellets with a substance having a modulating effect on active ingredient release
EP1868580A1 (en) * 2005-03-29 2007-12-26 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
ES2646326T3 (en) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0707325A2 (en) * 2006-01-27 2011-05-03 Eurand Inc multiparticulate release dosage formulation and method for preparing same
RU2490012C2 (en) * 2006-01-27 2013-08-20 Апталис Фарматех Инк Drug delivery systems containing weakly alkaline selective 5-ht3 serotonine antagonist and organic acids
SI3095447T1 (en) 2006-02-03 2022-02-28 Opko Renal, Llc Treatment shortages vitamin D s 25-hydroxyvitamin D2 in 25-hydroxyvitamin D3
NZ573382A (en) * 2006-05-09 2012-02-24 Boehringer Ingelheim Int Use of flibanserin for the treatment of post-menopausal sexual desire disorders
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
ATE456369T1 (en) 2006-06-30 2010-02-15 Boehringer Ingelheim Int FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
BRPI0716436B8 (en) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int controlled release system and method for manufacturing it
EP2056792B1 (en) * 2006-08-31 2023-06-07 Adare Pharmaceuticals, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
US10888521B2 (en) * 2007-03-02 2021-01-12 Farnam Companies, Inc. Sustained release compositions using wax-like materials
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CA2682015A1 (en) * 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP3225243B1 (en) * 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
PL3542792T3 (en) 2007-04-25 2023-11-20 Eirgen Pharma Ltd. Controlled release 25-hydroxyvitamin d
CL2008002693A1 (en) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
KR101500792B1 (en) 2008-01-10 2015-03-09 에보니크 룀 게엠베하 Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (en) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 Compositions comprising weakly basic drugs and controlled-release dosage forms
ES2477552T3 (en) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RS60087B1 (en) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Methods and compositions for reducing parathyroid levels
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2012154892A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
CN102579404A (en) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 Sustained-release capsule containing propiverine hydrochloride and preparation method of sustained-release capsule
CN102743756A (en) * 2012-07-24 2012-10-24 兆科药业（广州）有限公司 Compound preparation of propiverine hydrochloride and alpha-receptor antagonist
JP6410790B2 (en) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3331502B1 (en) 2015-08-07 2021-05-26 Santa Farma Ilaç Sanayi A.S. Controlled release propiverine formulations
AU2017253821B2 (en) 2016-03-28 2022-11-03 Opko Ireland Global Holdings, Limited Methods of vitamin D treatment
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
TR201918013A2 (en) * 2019-11-19 2021-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PELLET COMPOSITION CONTAINING PROPIVERIN OR A PHARMACEUTICALLY ACCEPTABLE SALT OF PROPIVERIN
EP4061369A4 (en) * 2019-11-19 2024-04-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical form comprising acidic substance
CN112152871B (en) * 2020-08-14 2021-09-24 上海纽盾科技股份有限公司 Artificial intelligence test method, device and system for network security equipment
EP4251154A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A.S. SUSPENDED RELEASE FORMULATIONS CONTAINING PROPIVERIN
WO2023128906A1 (en) * 2021-12-30 2023-07-06 Santa Farma Ilac Sanayii A.S. Release of propiverine compositions in gastric conditions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD139212A1 (en) 1978-10-09 1979-12-19 Christian Starke PROCESS FOR THE PREPARATION OF A NEW MEDICAMENT FROM ALPHA, ALPHA-DIPHENYL-ALPHA-ALKOXY ACETIC ACID 1-METHYLPIPERIDYL-4-ESTER DERIVATIVES
DE3000979A1 (en) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
DE3124090A1 (en) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach NEW ORAL DIPYRIDAMOL FORMS
DE3126703A1 (en) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach BROMHEXIN RETARD FORM AND METHOD FOR THEIR PRODUCTION
GB8616669D0 (en) 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
JPS63154619A (en) 1986-12-17 1988-06-27 Kowa Yakuhin Kogyo Kk Remedy for pollakiuria and residual urine feeling
SE8803822D0 (en) 1988-10-26 1988-10-26 NOVEL DOSAGE FORM
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
DE69017915T2 (en) 1989-10-26 1995-07-27 Nippon Shinyaku Co Ltd PREPARATION FOR THE STOMACH.
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
ZA97976B (en) 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US6190591B1 (en) 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
CA2311755C (en) 1998-08-27 2010-03-23 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
DE59905248D1 (en) * 1999-01-29 2003-05-28 Disphar Int Bv PHARMACEUTICAL COMPOSITIONS
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP2001039873A (en) 1999-08-02 2001-02-13 Nichiban Co Ltd Percutaneous absorption type therapeutic agent for dysuria
EP1227800A1 (en) 1999-10-29 2002-08-07 Merck & Co., Inc. Osmotic controlled release drug delivery device
EP1229026A4 (en) 1999-11-10 2003-09-24 Takeda Chemical Industries Ltd ALKOXYIMINOALKANSÄURE DERIVATIVES
JP2001048783A (en) 2000-01-01 2001-02-20 Lead Chemical Co Ltd Percutaneous absorption type pollakiuria / urinary incontinence treatment
IL141235A (en) 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the manufacture of a medicament for the treatment of benign prostatic hyperplasia
CN1660435A (en) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 new drug combination
DE20023135U1 (en) * 2000-04-03 2003-04-03 Beisel, Günther, 40789 Monheim Agents with improved prolonged release
PL201766B1 (en) * 2001-01-31 2009-05-29 Roehm Gmbh Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
CN1192767C (en) * 2001-02-27 2005-03-16 罗姆两合公司 Coatings and binders for pharmaceutical preparations with improved storage stability
ITMI20011446A1 (en) 2001-07-06 2003-01-06 Altergon Sa PHARMACEUTICAL COMPOSITIONS OF SUSCEPTIBLE ACTIVE INGREDIENTS OF UNLAWFUL ADMINISTRATION
DE10149674A1 (en) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration

Similar Documents

Publication Publication Date Title
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
HRPK20040323B3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
PL356358A1 (en) Solid dosage form of someticone for oral administration
ITMI20011337A0 (en) ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE INGREDIENT
AU6089200A (en) Rapid immediate release oral dosage form
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
HUP0101597A3 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
FI20000780L (en) Oral dosage form for controlled release of the drug
ITMI20011338A0 (en) ORAL PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
GB0107751D0 (en) Pharmaceutically active compounds
GB0106631D0 (en) Pharmaceutically active compounds
GB0105893D0 (en) Pharmaceutically active compounds
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
AU2003242538A1 (en) Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2002365863A1 (en) The use of cck-8 for the preparation of a pharmaceutical composition against inflammatory disorders
HK1056325A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
SI1077703T1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
AU2001272787B2 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
AU2001293278A1 (en) Tableted oral extended release dosage form
AU2002304093A1 (en) Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
AUPR738001A0 (en) Compound for medicinal purposes
AU2001272787A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient